Findings

What do systematic reviews say?

304 questions · 310 findings · 24 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 96 · 31%GRADE not reported 20 · 6.5%Very low 83 · 26.8%Low 70 · 22.6%Moderate 30 · 9.7%High 11 · 3.5%

Amifostine vs no intervention

Mean GI symptom scores · People with urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: IMRT vs 3DCRT

Mean GI symptom scores (EORTC‐QLQPR25 scale; lower scores better) · People with urological (prostate) and gynaecological (cervical) cancer

Summary of findings: IMRT showed no clear difference in mean GI symptom scores (EORTC‐QLQPR25 scale; lower scores better) compared with 3DCRT (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 181 participants
Low

Amifostine vs no intervention

Acute and late GI toxicity (grade 2+) · People with urological, gynaecological or colorectal cancer

Summary of findings: Amifostine may leads to lower acute and late GI toxicity (grade 2+) compared with no intervention (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.25
3 studies · 278 participants
Low

Amifostine vs no intervention

Diarrhoea (grade 2+) · People with urological, gynaecological or colorectal cancer

It is very uncertain whether summary of findings: Amifostine changes diarrhoea (grade 2+) during treatment compared with no intervention (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.25 [0.06, 0.98]
1 study · 36 participants
Very low

Amifostine vs no intervention

QoL · People with urological, gynaecological or colorectal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: IMRT vs 3DCRT

Acute and late GI toxicity (grade 2+) · People with urological (prostate) and gynaecological (cervical) cancer

Summary of findings: IMRT may leads to lower acute and late GI toxicity Grade 2+ compared with 3DCRT (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.48 [0.26, 0.88]
4 studies · 444 participants
Low

Summary of findings: Bile acid sequestrants vs no intervention

Mean GI symptom scores (during RT) · People with pelvic cancer

It is very uncertain whether summary of findings: Bile acid sequestrants changes mean GI symptom scores (during RT) compared with no intervention (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
MD 0.5
1 study · 33 participants
Very low

Summary of findings: Bile acid sequestrants vs no intervention

Acute and late GI toxicity (grade 2+) · People with pelvic cancer

Summary of findings: Bile acid sequestrants may leads to higher acute and late GI toxicity (grade 2+) compared with no intervention (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 4.24 [1.07, 16.7]
1 study · 33 participants
Low

Summary of findings: Bile acid sequestrants vs no intervention

Diarrhoea (grade 2+) · People with pelvic cancer

It is very uncertain whether summary of findings: Bile acid sequestrants changes diarrhoea (grade 2+) compared with no intervention (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 2.82 [0.66, 12.01]
1 study · 33 participants
Very low

Summary of findings: Bile acid sequestrants vs no intervention

QoL · People with pelvic cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Misoprostol vs placebo

Outcomes1 · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Misoprostol vs placebo

Mean GI symptom scores · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Misoprostol vs placebo

Acute and late GI toxicity (grade 2+) · Men with prostate cancer

Summary of findings: Misoprostol showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.38 [0.76, 2.51]
1 study · 100 participants
Low

Misoprostol vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

It is very uncertain whether summary of findings: Misoprostol changes diarrhoea (grade 2+) compared with placebo (very low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1 [0.46, 2.19]
1 study · 100 participants
Very low

Misoprostol vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: IMRT vs 3DCRT

Diarrhoea (grade 2+) · People with urological (prostate) and gynaecological (cervical) cancer

Summary of findings: IMRT may leads to lower diarrhoea (grade 2+) compared with 3DCRT (low certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 0.38 [0.22, 0.68]
1 study · 72 participants
Low

Summary of findings: Magnesium oxide vs placebo

Mean GI symptom scores (during RT) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Magnesium oxide vs placebo

Acute and late GI toxicity (grade 2+) · Men with prostate cancer

Summary of findings: Magnesium oxide showed no clear difference in acute and late GI toxicity (grade 2+) compared with placebo (moderate certainty).

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
RR 1.7 [0.87, 3.31]
1 study · 92 participants
Moderate

Summary of findings: Magnesium oxide vs placebo

Diarrhoea (grade 2+) · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: Magnesium oxide vs placebo

QoL · Men with prostate cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic… 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found